StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, will host a webcast to discuss the six-month interim results from the first cohort in its Phase II PathwayTM Study in cervical spinal cord injury. The Company will also provide a progress update on the second 40-patient cohort which is currently enrolling patients.
LINK
StemCells, Inc. Announces Webcast to Discuss Interim Results
LINK
0 commentaires:
Enregistrer un commentaire